CERO on OTC
CERO THERAPEUTICS HOLDINGS, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Cash | $1.1M8 | $475.9K3 | $96.9K3 | $3.3M5 | $1.7M5 | |
| Current assets | $1.4M8 | $42.4M8 | $2.0M4 | $3.7M5 | $2.7M5 | |
| Total assets | $180.1M8 | $42.4M3 | $5.1M4 | $6.2M5 | $3.6M5 | |
| Current liabilities | $98.1K8 | $30.7M3 | $3.5M4 | $7.4M5 | $9.1M5 | |
| Total liabilities | $9.2M8 | $39.9M3 | $5.1M4 | $8.1M5 | $9.1M5 | |
| Shareholders’ equity | -$7.7M3 | -$11.0M3 | -$42.1M4 | -$1.9M5 | -$5.4M5 | |
| Shares outstanding | 5.8K shares4 | 14.7M shares3 | 5.6M shares9 | 36.8M shares10 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Compare CERO THERAPEUTICS HOLDINGS, INC. with another company
Former names
- PHOENIX BIOTECH ACQUISITION CORP.Jul 8, 2021 to Feb 14, 20242
Recent filings
- Oct 7, 20268-K CURRENT REPORT
- Aug 31, 20268-K CURRENT REPORT
- Aug 14, 2026SCHEDULE 13G/A
- Aug 14, 202610-Q QUARTERLY REPORT
- Aug 14, 2026424B3 PROSPECTUS SUPPLEMENT
- Jul 17, 20268-K CURRENT REPORT
- Jul 17, 2026424B3 PROSPECTUS SUPPLEMENT
- Jul 13, 202625-NSE
- Jun 26, 20268-K CURRENT REPORT
- Jun 26, 2026424B3 PROSPECTUS SUPPLEMENT
- May 29, 20268-K CURRENT REPORT
- May 29, 2026424B3 PROSPECTUS SUPPLEMENT
- May 15, 202610-Q QUARTERLY REPORT
- May 15, 2026424B3 PROSPECTUS SUPPLEMENT
- May 1, 2026424B3 PROSPECTUS SUPPLEMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10